Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

PI3K inhibitors synergize with FGFR inhibitors to enhance antitumor responses in FGFR2-mutant endometrial cancers.

Packer L, Geng X, Bonazzi VF, Ju R, Mahon C, Cummings MC, Stephenson SA, Pollock PM.

Mol Cancer Ther. 2017 Jan 23. pii: molcanther.0415.2016. doi: 10.1158/1535-7163.MCT-16-0415. [Epub ahead of print]

PMID:
28119489
2.

The "melanoma-enriched" microRNA miR-4731-5p acts as a tumour suppressor.

Stark MS, Tom LN, Boyle GM, Bonazzi VF, Soyer HP, Herington AC, Pollock PM, Hayward NK.

Oncotarget. 2016 Aug 2;7(31):49677-49687. doi: 10.18632/oncotarget.10109.

3.

The NIH Big Data to Knowledge (BD2K) initiative.

Bourne PE, Bonazzi V, Dunn M, Green ED, Guyer M, Komatsoulis G, Larkin J, Russell B.

J Am Med Inform Assoc. 2015 Nov;22(6):1114. doi: 10.1093/jamia/ocv136. No abstract available.

4.

miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma.

Stark MS, Bonazzi VF, Boyle GM, Palmer JM, Symmons J, Lanagan CM, Schmidt CW, Herington AC, Ballotti R, Pollock PM, Hayward NK.

Oncotarget. 2015 Jul 10;6(19):17753-63.

5.

Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma.

Aoude LG, Pritchard AL, Robles-Espinoza CD, Wadt K, Harland M, Choi J, Gartside M, Quesada V, Johansson P, Palmer JM, Ramsay AJ, Zhang X, Jones K, Symmons J, Holland EA, Schmid H, Bonazzi V, Woods S, Dutton-Regester K, Stark MS, Snowden H, van Doorn R, Montgomery GW, Martin NG, Keane TM, López-Otín C, Gerdes AM, Olsson H, Ingvar C, Borg A, Gruis NA, Trent JM, Jönsson G, Bishop DT, Mann GJ, Newton-Bishop JA, Brown KM, Adams DJ, Hayward NK.

J Natl Cancer Inst. 2014 Dec 13;107(2). pii: dju408. doi: 10.1093/jnci/dju408.

6.

Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype.

Ohanna M, Cheli Y, Bonet C, Bonazzi VF, Allegra M, Giuliano S, Bille K, Bahadoran P, Giacchero D, Lacour JP, Boyle GM, Hayward NF, Bertolotto C, Ballotti R.

Oncotarget. 2013 Dec;4(12):2212-24.

7.

MicroRNA regulation of melanoma progression.

Bonazzi VF, Stark MS, Hayward NK.

Melanoma Res. 2012 Apr;22(2):101-13. doi: 10.1097/CMR.0b013e32834f6fbb. Review.

PMID:
22209751
8.

Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing.

Stark MS, Woods SL, Gartside MG, Bonazzi VF, Dutton-Regester K, Aoude LG, Chow D, Sereduk C, Niemi NM, Tang N, Ellis JJ, Reid J, Zismann V, Tyagi S, Muzny D, Newsham I, Wu Y, Palmer JM, Pollak T, Youngkin D, Brooks BR, Lanagan C, Schmidt CW, Kobe B, MacKeigan JP, Yin H, Brown KM, Gibbs R, Trent J, Hayward NK.

Nat Genet. 2011 Dec 25;44(2):165-9. doi: 10.1038/ng.1041.

9.

A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma.

Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V, Gartside M, Cust AE, Haq R, Harland M, Taylor JC, Duffy DL, Holohan K, Dutton-Regester K, Palmer JM, Bonazzi V, Stark MS, Symmons J, Law MH, Schmidt C, Lanagan C, O'Connor L, Holland EA, Schmid H, Maskiell JA, Jetann J, Ferguson M, Jenkins MA, Kefford RF, Giles GG, Armstrong BK, Aitken JF, Hopper JL, Whiteman DC, Pharoah PD, Easton DF, Dunning AM, Newton-Bishop JA, Montgomery GW, Martin NG, Mann GJ, Bishop DT, Tsao H, Trent JM, Fisher DE, Hayward NK, Brown KM.

Nature. 2011 Nov 13;480(7375):99-103. doi: 10.1038/nature10630.

10.

Cross-platform array screening identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as genes frequently silenced by methylation in melanoma.

Bonazzi VF, Nancarrow DJ, Stark MS, Moser RJ, Boyle GM, Aoude LG, Schmidt C, Hayward NK.

PLoS One. 2011;6(10):e26121. doi: 10.1371/journal.pone.0026121.

11.

Minimum information about a marker gene sequence (MIMARKS) and minimum information about any (x) sequence (MIxS) specifications.

Yilmaz P, Kottmann R, Field D, Knight R, Cole JR, Amaral-Zettler L, Gilbert JA, Karsch-Mizrachi I, Johnston A, Cochrane G, Vaughan R, Hunter C, Park J, Morrison N, Rocca-Serra P, Sterk P, Arumugam M, Bailey M, Baumgartner L, Birren BW, Blaser MJ, Bonazzi V, Booth T, Bork P, Bushman FD, Buttigieg PL, Chain PS, Charlson E, Costello EK, Huot-Creasy H, Dawyndt P, DeSantis T, Fierer N, Fuhrman JA, Gallery RE, Gevers D, Gibbs RA, San Gil I, Gonzalez A, Gordon JI, Guralnick R, Hankeln W, Highlander S, Hugenholtz P, Jansson J, Kau AL, Kelley ST, Kennedy J, Knights D, Koren O, Kuczynski J, Kyrpides N, Larsen R, Lauber CL, Legg T, Ley RE, Lozupone CA, Ludwig W, Lyons D, Maguire E, Methé BA, Meyer F, Muegge B, Nakielny S, Nelson KE, Nemergut D, Neufeld JD, Newbold LK, Oliver AE, Pace NR, Palanisamy G, Peplies J, Petrosino J, Proctor L, Pruesse E, Quast C, Raes J, Ratnasingham S, Ravel J, Relman DA, Assunta-Sansone S, Schloss PD, Schriml L, Sinha R, Smith MI, Sodergren E, Spo A, Stombaugh J, Tiedje JM, Ward DV, Weinstock GM, Wendel D, White O, Whiteley A, Wilke A, Wortman JR, Yatsunenko T, Glöckner FO.

Nat Biotechnol. 2011 May;29(5):415-20. doi: 10.1038/nbt.1823.

12.

Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor.

Boyle GM, Woods SL, Bonazzi VF, Stark MS, Hacker E, Aoude LG, Dutton-Regester K, Cook AL, Sturm RA, Hayward NK.

Pigment Cell Melanoma Res. 2011 Jun;24(3):525-37. doi: 10.1111/j.1755-148X.2011.00849.x.

PMID:
21435193
13.

The National Tumor Association Foundation (ANT): A 30 year old model of home palliative care.

Casadio M, Biasco G, Abernethy A, Bonazzi V, Pannuti R, Pannuti F.

BMC Palliat Care. 2010 Jun 8;9:12. doi: 10.1186/1472-684X-9-12.

14.

Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).

Dry JR, Pavey S, Pratilas CA, Harbron C, Runswick S, Hodgson D, Chresta C, McCormack R, Byrne N, Cockerill M, Graham A, Beran G, Cassidy A, Haggerty C, Brown H, Ellison G, Dering J, Taylor BS, Stark M, Bonazzi V, Ravishankar S, Packer L, Xing F, Solit DB, Finn RS, Rosen N, Hayward NK, French T, Smith PD.

Cancer Res. 2010 Mar 15;70(6):2264-73. doi: 10.1158/0008-5472.CAN-09-1577.

15.

The NIH Human Microbiome Project.

NIH HMP Working Group., Peterson J, Garges S, Giovanni M, McInnes P, Wang L, Schloss JA, Bonazzi V, McEwen JE, Wetterstrand KA, Deal C, Baker CC, Di Francesco V, Howcroft TK, Karp RW, Lunsford RD, Wellington CR, Belachew T, Wright M, Giblin C, David H, Mills M, Salomon R, Mullins C, Akolkar B, Begg L, Davis C, Grandison L, Humble M, Khalsa J, Little AR, Peavy H, Pontzer C, Portnoy M, Sayre MH, Starke-Reed P, Zakhari S, Read J, Watson B, Guyer M.

Genome Res. 2009 Dec;19(12):2317-23. doi: 10.1101/gr.096651.109.

16.

H-cadherin expression reduces invasion of malignant melanoma.

Kuphal S, Martyn AC, Pedley J, Crowther LM, Bonazzi VF, Parsons PG, Bosserhoff AK, Hayward NK, Boyle GM.

Pigment Cell Melanoma Res. 2009 Jun;22(3):296-306. doi: 10.1111/j.1755-148X.2009.00568.x.

PMID:
19368692
17.

Identification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma.

Bonazzi VF, Irwin D, Hayward NK.

Genes Chromosomes Cancer. 2009 Jan;48(1):10-21. doi: 10.1002/gcc.20615.

PMID:
18803327
18.

Electrochemotherapy a novel approach to the treatment of metastatic nodules on the skin and subcutaneous tissues.

Giardino R, Fini M, Bonazzi V, Cadossi R, Nicolini A, Carpi A.

Biomed Pharmacother. 2006 Sep;60(8):458-62. Review.

PMID:
16930935
19.

Thyroid nodule evaluation: what have we really learned from recent clinical guidelines?

Carpi A, Mechanick JI, Nicolini A, Rubello D, Iervasi G, Bonazzi V, Giardino R.

Biomed Pharmacother. 2006 Sep;60(8):393-5. Review.

PMID:
16905290
20.

Complementation analyses suggest species-specific functions of the SNF5 homology domain.

Bonazzi V, Medjkane S, Quignon F, Delattre O.

Biochem Biophys Res Commun. 2005 Oct 21;336(2):634-8.

PMID:
16154112

Supplemental Content

Loading ...
Support Center